Duloxetine
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Duloxetine: From Depression and Anxiety Disorders to Obsessive-Compulsive Disorder
One-Sentence Summary
Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) established in clinical practice for major depressive disorder, generalised anxiety disorder, diabetic peripheral neuropathic pain and fibromyalgia. The TxGNN model’s top-scoring candidates span ten different diseases, but only two carry meaningful supporting evidence: Obsessive-Compulsive Disorder (99.84% score, one completed Phase 4 trial) and Agoraphobia/panic disorder spectrum (99.84% score, three supporting publications). The remaining eight candidates (including the single highest-scoring hit, benign paroxysmal torticollis of infancy) have no clinical trials or literature support and are best treated as unvalidated model signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Major depressive disorder, generalised anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia (established clinical use; not captured in this dataset — UK regulatory records for this candidate are empty) |
| Predicted New Indication | Obsessive-Compulsive Disorder |
| TxGNN Prediction Score | 99.84% |
| Evidence Level | L3 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for this candidate record is not available. Based on well-established public pharmacological knowledge, duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI), and its efficacy in major depressive disorder and generalised anxiety disorder is well proven. Serotonergic dysregulation is central to the pathophysiology of obsessive-compulsive disorder, and selective serotonin reuptake inhibitors (SSRIs) are the established first-line pharmacological treatment for OCD.
Since duloxetine shares the serotonergic reuptake-inhibition mechanism with SSRIs, and OCD frequently co-occurs with, and shares neurobiological overlap with, anxiety and mood disorders that duloxetine already treats, a mechanistic rationale for extending its use to OCD is plausible. This is supported by an existing, if small, dedicated clinical trial (below) rather than purely theoretical reasoning.
The same serotonergic/noradrenergic mechanism also underlies the report’s secondary candidate, agoraphobia (part of the panic disorder spectrum), for which duloxetine has direct open-label clinical evidence — see the supplementary section below.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT00464698 | Phase 4 | Completed | 20 | Pilot study assessing duloxetine efficacy specifically for OCD treatment — the only trial directly designed for this repurposing hypothesis, but small and non-comparative |
| NCT02476136 | N/A | Unknown | 8,800 | Large individual-patient-data meta-analysis of antidepressant efficacy across anxiety disorders; may include duloxetine data but is not OCD-specific |
| NCT01404871 | N/A | Completed | 26 | Investigates predictors of medication response in OCD; duloxetine used as an alternative arm for patients who had already tried standard agents |
| NCT05930912 | N/A | Unknown | 1 | Psychoanalytic treatment study of ASD psychiatric comorbidities (including OCD); minimal relevance given n=1 |
| NCT01944657 | N/A | Withdrawn | 0 | TMS vs. medication monotherapy for major depression; withdrawn with no enrolment, not OCD-specific |
Literature Evidence
Currently no related literature available for the obsessive-compulsive disorder indication specifically.
Supplementary Candidate: Agoraphobia (Panic Disorder Spectrum)
This evidence pack scored agoraphobia almost identically to OCD (99.84%, L3, “Research Question” stage) and it carries supporting literature not seen for OCD, so it is included here for completeness rather than as a separate report.
Clinical trials:
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT05930912 | N/A | Unknown | 1 | ASD psychiatric comorbidity study; not specifically designed for agoraphobia, weak relevance |
Literature:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 19228176 | 2009 | Open-label trial | CNS Neuroscience & Therapeutics | Open-label support for duloxetine in panic disorder with or without agoraphobia (n=15) |
| 24294001 | 2013 | Case report | Neuropsychiatric Disease and Treatment | Case report of duloxetine treating panic disorder presenting with somatic gastric pain |
| 23313564 | 2013 | RCT (biomarker substudy) | Progress in Neuro-Psychopharmacology & Biological Psychiatry | BDNF biomarker substudy from a duloxetine RCT in generalised anxiety disorder (not agoraphobia-specific) |
Other Candidates Screened (Low Confidence)
The remaining eight TxGNN hits — including the single highest-scoring prediction — returned zero clinical trials and zero literature on targeted searches, and no plausible mechanistic link to an SNRI:
| Disease | Score | Evidence Level | Recommendation |
|---|---|---|---|
| Benign paroxysmal torticollis of infancy | 99.85% | L5 | Hold |
| Histrionic personality disorder | 99.78% | L5 | Hold |
| Paranoid personality disorder | 99.78% | L5 | Hold |
| Schizoid personality disorder | 99.78% | L5 | Hold |
| Schizotypal personality disorder | 99.78% | L5 | Hold |
| Ohdo syndrome and variants | 99.69% | L5 | Hold |
| Ligneous conjunctivitis | 99.66% | L5 | Hold |
| Blepharophimosis–intellectual disability syndrome, Ohdo type | 99.60% | L5 | Hold |
These illustrate that raw TxGNN score alone does not track evidence quality — several rare genetic/congenital syndromes score higher than OCD despite having no known pharmacological connection to duloxetine.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: Only one small (n=20), non-comparative Phase 4 trial directly supports duloxetine in OCD, and no literature confirms it; agoraphobia is similarly supported by only an open-label study and a case report. Neither reaches the L1/L2 threshold needed to proceed, and this candidate has a Blocking data gap on UK/manufacturer safety labelling (warnings, contraindications) that must be resolved before any S1 safety evaluation.
To proceed, the following is needed:
- MHRA product labelling (SmPC) — key warnings, contraindications and drug interactions (currently a Blocking data gap)
- Confirmed mechanism-of-action documentation from DrugBank or an equivalent source
- A larger, comparator-controlled trial of duloxetine in OCD to replace the existing 20-patient pilot
- Dedicated agoraphobia-specific trial data, since current literature addresses panic disorder more broadly
- UK marketing authorisation and market-status confirmation, as none is currently on file for this candidate
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.